Close Menu

multiple myeloma

Idecabtagene vicleucel is a B-cell maturation antigen-directed CAR T-cell immunotherapy being developed as a treatment for patients with relapsed and refractory multiple myeloma.

With at-home testing and online, patient-centered reports, the CureCloud initiative sets out to break down barriers to targeted treatment options while building a broad patient dataset.

Investigators plan to tap into large genomic and other datasets with an in silico patient to simulate drug responses, uncover treatment targets, and assess therapies.

GNS Healthcare will apply its AI and simulation technology to data from the CoMMpass study in search of insights on disease progression and drug response.

The team wants to create NK cell therapies from induced pluripotent stem cells and aims to achieve proof-of-concept for their technology in multiple myeloma.

The first phase of the study to evaluate Telo Genomics' telomere analytics as a prognostic solution for multiple myeloma is expected to launch in Q1 2020.

A structural variant analysis based on genome sequences for almost 800 multiple myeloma cases suggests a IgL translocation present in nearly 10 percent of patients may inform survival.

The platform integrates whole exome and RNA sequencing for downstream RNA-based drug repurposing to treat patients with relapsed multiple myeloma.

Evidence is accumulating that analyzing cell-free DNA and/or samples from circulating tumor cells provides a good surrogate for bone marrow in these patients.

Sebia and Janssen Biotech collaborated on the development of the test, which is for assessing patients treated with Darzalex.